Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aclaris Therapeutics Inc. (ACRS)

10.81   -0.06 (-0.55%) 01-16 05:36
Open: 10.67 Pre. Close: 10.87
High: 11.04 Low: 10.42
Volume: 451,275 Market Cap: 662M
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 11.052 - 11.142 11.142 - 11.203
Low: 10.239 - 10.335 10.335 - 10.4
Close: 10.681 - 10.834 10.834 - 10.936

Technical analysis

as of: 2022-01-15 8:44:08 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 15.88     One year: 18.17
Support: Support1: 10.42    Support2: 8.67
Resistance: Resistance1: 13.60    Resistance2: 15.56
Pivot: 13.25
Moving Average: MA(5): 11.62     MA(20): 13.61
MA(100): 15.40     MA(250): 18.56
MACD: MACD(12,26): -0.73     Signal(9): -0.37
Stochastic oscillator: %K(14,3): 7.39     %D(3): 13.61
RSI: RSI(14): 27.92
52-week: High: 30.38  Low: 10.42  Change(%): -40.1
Average Vol(K): 3-Month: 41821  10-Days: 56989

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
ACRS has closed above bottom band by 6.8%. Bollinger Bands are 79.8% wider than normal. The large width of the bands suggest high volatility as compared to ACRS's normal range. The bands have been in this wide range for 2 bars. This is a sign that the current trend might continue.

Headline News

Fri, 14 Jan 2022
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Wed, 12 Jan 2022
Health Care Sector Update for 01/12/2022: ACRS,VCEL,NPCE,IRIX - Nasdaq

Wed, 12 Jan 2022
Healthcare Stocks Making Moves Wednesday: IMRN, VAXX, ERAS, MYNZ, NTRB, PHG, BBLG, ACRS - InvestorsObserver

Mon, 20 Dec 2021
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages - MarketBeat

Fri, 03 Dec 2021
Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine - GlobeNewswire

Thu, 18 Nov 2021
Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021 - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 61
Shares Float (M) 46
% Held by Insiders 4.14
% Held by Institutions 93.68
Shares Short (K) 2,050
Shares Short P. Month (K) 1,880

Stock Financials

EPS -1.550
EPS Est This Year -3.100
EPS Est Next Year -3.170
Book Value (p.s.) 3.540
Profit Margin
Operating Margin -851.62
Return on Assets (ttm) -21.7
Return on Equity (ttm) -63.5
Qtrly Rev. Growth 14.5
Gross Profit (p.s.) -0.457
Sales Per Share 0.112
EBITDA (p.s.) -0.943
Qtrly Earnings Growth
Operating Cash Flow (M) -44
Levered Free Cash Flow (M) -22

Stock Valuations

PE Ratio -6.97
PEG Ratio
Price to Book value 3.05
Price to Sales 96.77
Price to Cash Flow -15.07

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.